Rybelsus vs. Contrave
Rybelsus and Contrave differ in their mechanisms and uses. Rybelsus, an oral GLP-1 receptor agonist, is approved for type 2 diabetes management and provides moderate weight loss. Contrave, a combination of naltrexone and bupropion, targets chronic weight management, with less pronounced weight-loss effects. Rybelsus commonly causes nausea and gastrointestinal discomfort, while Contrave may lead to mood changes and insomnia. Rybelsus costs $875/month, while Contrave costs around $300/month. Neither drug currently faces shortages.
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, diarrhea, vomiting, and abdominal pain.
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions
Bupropion enhances dopamine and norepinephrine activity, reducing appetite and cravings; Naltrexone modulates the brain’s reward system, reducing cravings and emotional eating behaviors by blocking opioid receptors.
Common Side Effects
Nausea, constipation, headache, dizziness, dry mouth, and insomnia.
Serious Potential Side Effects
Increased blood pressure, seizures (rare), suicidal thoughts, and liver damage.